<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563951</url>
  </required_header>
  <id_info>
    <org_study_id>GNS-CL001</org_study_id>
    <nct_id>NCT02563951</nct_id>
  </id_info>
  <brief_title>Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers</brief_title>
  <official_title>A Phase I Pharmacokinetic Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maxinase Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maxinase Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the pharmacokinetics (PK), safety and tolerability of&#xD;
      3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS)&#xD;
      as compared to Granisetron IV Injection and Granisetron Tablet in healthy Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Parameter: Area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC(0-∞)) for 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of GNS and Granisetron IV Injection</measure>
    <time_frame>within 1 hour prior to drug administration; 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Area under the plasma concentration-time curve from zero (0) hours to last quantifiable concentration(t) (AUC(0-t)) for 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of GNS and Granisetron IV Injection</measure>
    <time_frame>within 1 hour prior to drug administration; 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Peak Plasma Concentration (Cmax) for 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of GNS and Granisetron IV Injection</measure>
    <time_frame>within 1 hour prior to drug administration; 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Area under the plasma concentration-time curve from zero (0) hours to infinity (∞) (AUC(0-∞)) for Granisetron Tablet</measure>
    <time_frame>within 1 hour prior to drug administration; 15, 30, 45 minutes, and 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Area under the plasma concentration-time curve from zero (0) hours to last quantifiable concentration (t) (AUC(0-t)) for Granisetron Tablet</measure>
    <time_frame>within 1 hour prior to drug administration; 15, 30, 45 minutes, and 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Peak Plasma Concentration (Cmax) for Granisetron Tablet</measure>
    <time_frame>within 1 hour prior to drug administration; 15, 30, 45 minutes, and 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Time to maximum plasma concentration (Tmax) for 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS) and Granisetron IV Injection</measure>
    <time_frame>within 1 hour prior to drug administration; 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Time to maximum plasma concentration (Tmax) for Granisetron Tablet</measure>
    <time_frame>within 1 hour prior to drug administration; 15, 30, 45 minutes, and 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: elimination constant rate (Kel) for 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS) and Granisetron IV Injection</measure>
    <time_frame>within 1 hour prior to drug administration; 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: elimination constant rate (Kel) for Granisetron Tablet</measure>
    <time_frame>within 1 hour prior to drug administration; 15, 30, 45 minutes, and 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: half-life (t1/2) for 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS) and Granisetron IV Injection</measure>
    <time_frame>within 1 hour prior to drug administration; 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: half-life (t1/2) for Granisetron Tablet</measure>
    <time_frame>within 1 hour prior to drug administration; 15, 30, 45 minutes, and 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: absolute bioavailability (F) for 3 intranasal (IN) doses (0.5, 1.0 and 2.0 mg) of Granisetron Hydrochloride Nasal Sprays (GNS) and Granisetron IV Injection</measure>
    <time_frame>within 1 hour prior to drug administration; 5, 10, 15, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: absolute bioavailability (F) for Granisetron Tablet</measure>
    <time_frame>within 1 hour prior to drug administration; 15, 30, 45 minutes, and 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Report adverse events and measure vital signs over trial period.</measure>
    <time_frame>These will be measured from 30 mins pre-dose to every 3 hours until 12 hours post-dose, then at 24 and 36 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECG assessment</measure>
    <time_frame>This will be measured at screening, and 24, 36 hours post-dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>GNS Spray 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One spray of GNS 0.5mg/spray into right nostril.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNS Spray 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One spray of GNS 0.5mg/spray into both left and right nostril.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GNS Spray 2.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One spray of GNS 1.0mg/spray into both left and right nostril.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kytril 1mg (IV injection)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A dose of 1mg of Granisetron IV injection (kytril 1mL, 3mg/mL/vial) will be administered as a slow IV injection (over 30 seconds)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kytril 1mg (Tablet)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single dose (kytril 1mg, one tablet) orally administered with 240mL of water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNS Spray 0.5mg</intervention_name>
    <arm_group_label>GNS Spray 0.5mg</arm_group_label>
    <other_name>Granisetron Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNS Spray 1.0mg</intervention_name>
    <arm_group_label>GNS Spray 1.0mg</arm_group_label>
    <other_name>Granisetron Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNS Spray 2.0mg</intervention_name>
    <arm_group_label>GNS Spray 2.0mg</arm_group_label>
    <other_name>Granisetron Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kytril 1mg (IV injection)</intervention_name>
    <arm_group_label>Kytril 1mg (IV injection)</arm_group_label>
    <other_name>Granisetron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kytril 1mg (Tablet)</intervention_name>
    <arm_group_label>Kytril 1mg (Tablet)</arm_group_label>
    <other_name>Granisetron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or females between the ages of 20-64 years&#xD;
&#xD;
          2. Body Mass Index (BMI) of 18.5 (inclusive) to 24 kg/m2; and a total body weight &gt;45 kg&#xD;
&#xD;
          3. Accessible vein for blood sampling&#xD;
&#xD;
          4. No significant abnormalities in electrocardiogram (ECG) recording as per sites' local&#xD;
             practice&#xD;
&#xD;
          5. No significant abnormalities in general physical examination as per sites' local&#xD;
             practice&#xD;
&#xD;
          6. No significantly abnormal findings in laboratory assessments including hematology,&#xD;
             biochemistry and urinalysis as per site's local practice&#xD;
&#xD;
          7. A signed and dated written informed consent must be obtained from the subject prior to&#xD;
             study participation&#xD;
&#xD;
          8. Capable of understanding and willing to comply with study procedures&#xD;
&#xD;
          9. A negative serum pregnancy test before the first dose of study drug must be available&#xD;
             for women of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, breast-feeding or have positive pregnancy test&#xD;
&#xD;
          2. History of hypersensitivity to granisetron or its analogs&#xD;
&#xD;
          3. Subjects with nasal ulcer, septal perforation, or other nasal conditions that may&#xD;
             interfere with nasal administration and determined by the investigator to be&#xD;
             ineligible&#xD;
&#xD;
          4. Subjects with a QT interval greater than 500 ms or with acute ischemic changes or&#xD;
             cardiac abnormality predisposing to arrhythmia on screening electrocardiogram (ECG) or&#xD;
             by history&#xD;
&#xD;
          5. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             other significant disease or clinical findings at screening and determined by the&#xD;
             investigator to be ineligible&#xD;
&#xD;
          6. Subjects with a history of drug and/or alcohol abuse within 12 months prior to dosing&#xD;
&#xD;
          7. Inability to read and/or sign the consent form&#xD;
&#xD;
          8. Treatment with any other investigational drug during the 4 weeks prior to the initial&#xD;
             dosing for this study&#xD;
&#xD;
          9. Subjects who have donated or lost more than 250 ml blood within 2 months prior to the&#xD;
             initial dosing for this study&#xD;
&#xD;
         10. Male and female subjects with reproductive potential who are not willing to use&#xD;
             effective method of contraception. Use of hormonal contraceptive is not allowed during&#xD;
             the study period&#xD;
&#xD;
         11. Clinical significant rhinitis or rhinorrhea at screening determined by the&#xD;
             investigator to be ineligible&#xD;
&#xD;
         12. Use of prescription or nonprescription drugs and dietary supplements within 7 days or&#xD;
             5 half-lives (whichever is longer) prior to dosing of study medication&#xD;
&#xD;
         13. For subjects who smoke or use tobacco products or are currently using nicotine&#xD;
             products (patches, gums, etc.), 2 weeks abstinence is required&#xD;
&#xD;
         14. Conditions upon screening which might contraindicate or require that caution be used&#xD;
             in the administration of granisetron&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai-Min Chu, M.D Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Neihu District</city>
        <state>Taipei City</state>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiation therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

